Tech Company Financing Transactions
Serina Therapeutics Funding Round
Private investors participated in a $5 million funding round for Serina Therapeutics. The round was announced on 4/9/2025.
Transaction Overview
Company Name
Announced On
4/9/2025
Transaction Type
Venture Equity
Amount
$5,000,000
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds from the transaction will support the continued development of SER-252 (POZ-apomorphine), Serina's lead clinical candidate for Advanced Parkinson's disease, as the company prepares to initiate a Phase 1 clinical trial in the fourth quarter of 2025.
Company Information
Company Status
Private & Independent
Industry
Healthcare Services
Mailing Address
601 Genome Way 2001
Huntsville, AL 35806
USA
Huntsville, AL 35806
USA
Phone
Website
Email Address
Not Recorded
Overview
Serina Therapeutics is a privately held biotechnology company located in Huntsville, Alabama. We have developed a proprietary, clinically-validated polymer technology based on the water-soluble polymer poly(oxazoline). We call it POZ for short.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Simba Gill
Chief Executive Officer
Steve Ledger
Chief Financial Officer
Greg Curhan
Vice President
Srini Tenjarla
VP - Bus. Development
Randall Moreadith
Browse more venture capital transactions:
Prev: 4/9/2025: Tailscale venture capital transaction
Next: 4/9/2025: Solve Intelligence venture capital transaction
Share this article
Where The Data Comes From
We report on funding rounds that are announced publicly. VC transactions on this site are derived from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs